Dimensions | Variables | β coeff. | 95% CI | P values |
---|---|---|---|---|
PF R2 = 0.31 | Intercept | 95.4 | [91.1; 99.6] | p < .0001 |
 | Female | -4.7 | [-7.6; -1.7] | p < 0.0018 |
 | Age ≥ 75 years | -23.3 | [-30.4; -16.2] | p < .0001 |
 | Low educational (primary or less) | -7.5 | [-11.2; -3.8] | p < .0001 |
 | Unemployment | -6.3 | [-9.4; -3.2] | p < .0001 |
 | BMI > 30 (kg/m2) | -5.8 | [-10; -1.6] | p < 0.0065 |
 | Critical illness in the last 4 weeks | -8.0 | [-14.9; -1.1] | p < 0.0237 |
 | Diabetes | -5.6 | [-10.1; -1] | p < 0.0163 |
 | Side effects related to general health | -17.0 | [-20.9; -13.1] | p < .0001 |
 | Side effects related to mental health | -6.8 | [-10.5; -3] | p < 0.0004 |
 | Recent surgery | -9.5 | [-24.9; 6] | p < 0.2283 |
 | Infectious disease in the last 4 weeks | -4.8 | [-9.1; -0.4] | p < 0.0311 |
RP R2 = 0.22 | Intercept | 90.5 | [82.8; 98.1] | p < .0001 |
 | Female | -6.9 | [-12.2; -1.6] | p < 0.0104 |
 | Age ≥ 75 years | -20.1 | [-33.1; -7] | p < 0.0026 |
 | Low educational (primary or less) | -11.4 | [-18; -4.8] | p < 0.0007 |
 | Hospitalization in the last 4 weeks | -17.9 | [-27.1; -8.8] | p < 0.0001 |
 | Critical illness in the last 4 weeks | -31.5 | [-44.8; -18.1] | p < .0001 |
 | Infectious disease in the last 4 weeks | -10.9 | [-19; -2.9] | p < 0.0080 |
 | Side effects related to general health | -21.5 | [-28.7; -14.3] | p < .0001 |
 | Side effects related to mental health | -16.0 | [-22.8; -9.1] | p < .0001 |
BP R2 = 0.23 | Intercept | 85.3 | [80.6; 90] | p < .0001 |
 | Female | -4.9 | [-8.1; -1.6] | p < 0.0035 |
 | Age ≥ 75 years | -8.3 | [-16.1; -0.4] | p < 0.0402 |
 | Low educational (primary or less) | -6.5 | [-10.5; -2.5] | p < 0.0016 |
 | Infectious disease in the last 4 weeks | -9.1 | [-14; -4.3] | p < 0.0002 |
 | Side effects related to general health | -18.7 | [-23.2; -14.2] | p < .0001 |
 | Side effects related to mental health | -9.7 | [-14; -5.4] | p < .0001 |
 | Side effects related to body modification | -4.2 | [-7.7; -0.7] | p < 0.0193 |
MH R2 = 0.24 | Intercept | 81.1 | [77.7; 84.6] | p < .0001 |
 | Female | -5.6 | [-8; -3.3] | p < .0001 |
 | Family status (living alone) | -4.6 | [-7.2; -1.9] | p < 0.0007 |
 | Duration of dialysis > 3 years | -3.3 | [-5.8; -0.8] | p < 0.0087 |
 | Hospitalization in the last 4 weeks | -7.7 | [-11.4; -4] | p < .0001 |
 | Side effects related to mental health | -16.5 | [-19.5; -13.5] | p < .0001 |
 | Side effects related to body modification | -4.4 | [-6.9; -1.9] | p < 0.0005 |
RE R2 = 0.18 | Intercept | 94.8 | [86.5; 103] | p < .0001 |
 | Female | -6.4 | [-12; -0.8] | p < 0.0252 |
 | Low educational (primary or less) | -16.8 | [-24; -9.6] | p < .0001 |
 | Age ≥ 75 years | -11.1 | [-25.3; 3.2] | p < 0.1285 |
 | Family status (living alone) | -9.1 | [-15.3; -2.8] | p < 0.0045 |
 | Hospitalization in the last 4 weeks | -17.4 | [-26.7; -8.1] | p < 0.0003 |
 | Infectious disease in the last 4 weeks | -19.1 | [-27.6; -10.7] | p < .0001 |
 | Side effects related to mental health | -25.0 | [-32; -18.1] | p < .0001 |
SF R2 = 0.25 | Intercept | 90.8 | [86.8; 94.8] | p < .0001 |
 | Female | -4.9 | [-7.6; -2.1] | p < 0.0006 |
 | Family status (living alone) | -4.6 | [-7.8; -1.5] | p < 0.0036 |
 | Hospitalization in the last 4 weeks | -11.8 | [-16.2; -7.3] | p < .0001 |
 | Infectious disease in the last 4 weeks | -7.2 | [-11.5; -2.9] | p < 0.0011 |
 | Diabetes | -7.5 | [-11.5; -3.5] | p < 0.0002 |
 | Side effects related to general health | -11.3 | [-15; -7.6] | p < .0001 |
 | Side effects related to mental health | -16.4 | [-20; -12.8] | p < .0001 |
VT R2 = 0.22 | Intercept | 62.8 | [59.6; 66.1] | p < .0001 |
 | Female | -2.4 | [-4.6; -0.1] | p < 0.0366 |
 | Hospitalization in the last 4 weeks | -8.3 | [-11.8; -4.8] | p < .0001 |
 | Side effects related to general health | -12 | [-15; -8.9] | p < .0001 |
 | Side effects related to mental health | -11.7 | [-14.8; -8.7] | p < .0001 |
 | Side effects related to body modification | -3.9 | [-6.3; -1.4] | p < 0.0020 |
GH R2 = 0.18 | Intercept | 63.8 | [62.1; 65.5] | p < .0001 |
 | Hospitalization in the last 4 weeks | -6.1 | [-10.2; -2] | p < 0.0038 |
 | Critical illness in the last 4 weeks | -7.1 | [-13.5; -0.7] | p < 0.0305 |
 | Diabetes | -5.4 | [-9; -1.7] | p < 0.0038 |
 | Side effects related to general health | -11.6 | [-15.1; -8.1] | p < .0001 |
 | Side effects related to mental health | -7.7 | [-11.1; -4.2] | p < .0001 |
 | Side effects related to body modification | -5.6 | [-8.4; -2.9] | p < .0001 |
 | Non-compliant | -6.3 | [-9.2; -3.4] | p < .0001 |
PCS (R2 = 0.28) | Intercept | 52.7 | [50.9; 54.5] | p < .0001 |
 | Female | -1.7 | [-3; -0.4] | p < 0.0084 |
 | Age ≥ 75 years | -7.7 | [-11; -4.3] | p < .0001 |
 | Low educational (primary or less) | -3.3 | [-4.9; -1.7] | p < .0001 |
 | Unemployment | -2.5 | [-3.8; -1.1] | p < 0.0003 |
 | Critical illness in the last 4 weeks | -5.7 | [-8.8; -2.6] | p < 0.0003 |
 | Infectious disease in the last 4 weeks | -3.2 | [-5.1; -1.3] | p < 0.0012 |
 | Side effects related to general health | -9.2 | [-10.8; -7.5] | p < .0001 |
MCS (R2 = 0.22) | Intercept | 52.1 | [50.3; 54] | p < .0001 |
 | Female | -1.7 | [-3; -0.4] | p < 0.0113 |
 | Family status (living alone) | -2.2 | [-3.7; -0.7] | p < 0.0039 |
 | Hospitalization in the last 4 weeks | -5.7 | [-7.8; -3.6] | p < .0001 |
 | Side effects related to body modification | -2.5 | [-3.9; -1.1] | p < 0.0005 |
 | Side effects related to mental health | -9.3 | [-11; -7.7] | p < .0001 |